| Systemic immunity is required for effective cancer immunotherapy MH Spitzer, Y Carmi, NE Reticker-Flynn, SS Kwek, D Madhireddy, ... Cell 168 (3), 487-502. e15, 2017 | 876 | 2017 |
| Highly multiplexed simultaneous detection of RNAs and proteins in single cells AP Frei, FA Bava, ER Zunder, EWY Hsieh, SY Chen, GP Nolan, ... Nature methods 13 (3), 269-275, 2016 | 340 | 2016 |
| High response rate to PD-1 blockade in desmoplastic melanomas Z Eroglu, JM Zaretsky, S Hu-Lieskovan, DW Kim, A Algazi, DB Johnson, ... Nature 553 (7688), 347-350, 2018 | 317 | 2018 |
| Epigenomic-guided mass cytometry profiling reveals disease-specific features of exhausted CD8 T cells B Bengsch, T Ohtani, O Khan, M Setty, S Manne, S O’Brien, PF Gherardini, ... Immunity 48 (5), 1029-1045. e5, 2018 | 290 | 2018 |
| AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation V Cianfanelli, C Fuoco, M Lorente, M Salazar, F Quondamatteo, ... Nature cell biology 17 (1), 20-30, 2015 | 272 | 2015 |
| An interactive reference framework for modeling a dynamic immune system MH Spitzer, PF Gherardini, GK Fragiadakis, N Bhattacharya, RT Yuan, ... Science 349 (6244), 1259425, 2015 | 267 | 2015 |
| CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label … MH O'Hara, EM O'Reilly, G Varadhachary, RA Wolff, ZA Wainberg, AH Ko, ... The lancet oncology 22 (1), 118-131, 2021 | 219 | 2021 |
| Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial LJ Padrón, DM Maurer, MH O’Hara, EM O’Reilly, RA Wolff, ZA Wainberg, ... Nature medicine 28 (6), 1167-1177, 2022 | 172 | 2022 |
| Convergent evolution of enzyme active sites is not a rare phenomenon PF Gherardini, MN Wass, M Helmer-Citterich, MJE Sternberg Journal of molecular biology 372 (3), 817-845, 2007 | 160 | 2007 |
| Comprehensive immune monitoring of clinical trials to advance human immunotherapy FJ Hartmann, J Babdor, PF Gherardini, EAD Amir, K Jones, B Sahaf, ... Cell reports 28 (3), 819-831. e4, 2019 | 113 | 2019 |
| Structure-based function prediction: approaches and applications PF Gherardini, M Helmer-Citterich Briefings in Functional Genomics and Proteomics 7 (4), 291-302, 2008 | 102 | 2008 |
| Deep proteomics of breast cancer cells reveals that metformin rewires signaling networks away from a pro-growth state F Sacco, A Silvestri, D Posca, S Pirrò, PF Gherardini, L Castagnoli, ... Cell Systems 2 (3), 159-171, 2016 | 91 | 2016 |
| Phosphoproteomic Analysis of Differentiating Leishmania Parasites Reveals a Unique Stage-Specific Phosphorylation Motif P Tsigankov, PF Gherardini, M Helmer-Citterich, GF Späth, D Zilberstein Journal of proteome research 12 (7), 3405-3412, 2013 | 88 | 2013 |
| Regulation dynamics of Leishmania differentiation: deconvoluting signals and identifying phosphorylation trends P Tsigankov, PF Gherardini, M Helmer-Citterich, GF Späth, PJ Myler, ... Molecular & Cellular Proteomics 13 (7), 1787-1799, 2014 | 86 | 2014 |
| Single-cell systems-level analysis of human Toll-like receptor activation defines a chemokine signature in patients with systemic lupus erythematosus WE O'Gorman, EWY Hsieh, ES Savig, PF Gherardini, JD Hernandez, ... Journal of Allergy and Clinical Immunology 136 (5), 1326-1336, 2015 | 84 | 2015 |
| Multiplexed detection and quantification of nucleic acids in single-cells AP Frei, GP Nolan, PF Gherardini, FA Bava US Patent App. 14/875,454, 2016 | 78 | 2016 |
| Exploring the diversity of SPRY/B30. 2-mediated interactions L Perfetto, PF Gherardini, NE Davey, F Diella, M Helmer-Citterich, ... Trends in biochemical sciences 38 (1), 38-46, 2013 | 78 | 2013 |
| Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in … MH O'Hara, EM O'Reilly, M Rosemarie, G Varadhachary, ZA Wainberg, ... Cancer research 79 (13_Supplement), CT004-CT004, 2019 | 57 | 2019 |
| Phospho3D 2.0: an enhanced database of three-dimensional structures of phosphorylation sites A Zanzoni, D Carbajo, F Diella, PF Gherardini, A Tramontano, ... Nucleic acids research 39 (suppl_1), D268-D271, 2010 | 54 | 2010 |
| Phospho3D: a database of three-dimensional structures of protein phosphorylation sites A Zanzoni, G Ausiello, A Via, PF Gherardini, M Helmer-Citterich Nucleic acids research 35 (suppl_1), D229-D231, 2007 | 52 | 2007 |